
    
      All enrolled patients will receive the following 3 drug combination: Saquinavir, Zidovudine
      and Lamivudine. Efficacy and duration of anti-viral response will be evaluated by monitoring
      of HIV-1 RNA levels. Patients below the detectable limit of 200 copies/ml will be analyzed
      using the Ultra-direct method with a detection limit of 20 copies/ml. CD4 and CD8 cell counts
      will also be analyzed.
    
  